Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has recently announced that it has decided to adopt Medidata Solutions Inc (NASDAQ:MDSO)’s risk-based monitoring (RBM) solutions apart from its clinical cloud solutions. While Infinity is already using Medidata Rave and Medidata Coder solutions for its Phase I-II and pre-clinical development programs, it has decided to use RBM for its Phase III oncology study.
Embracing Medidata’s solutions
Through extending the use of Medidata’s solutions, Infinity Pharmaceuticals Inc. (NASDAQ:INFI) aims to enhance its outsourcing model along with drug development strategy. The move echoes the similar move of other clinical research organization and research institutes such as JCR Pharmaceuticals, CTI, Cancer Research UK, etc., which have adopted Medidata’s cloud-based solutions.
DUO study development
Another remarkable development that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) reported in the recent days relates to its progress in Phase III DUO study of duvelisib. The study aims to determine the efficacy and safety of dubelisib as against Novartis AG (ADR)
(NYSE:NVS)’s NVS Arzerra, which is meant for the treatment of relapsed chronic lymphocytic leukemia (CLL) patients,. During last month, the company announced the completion of the enrollment of 300 patients in phase III DUO study as per the set target.
It is worthy to note that duvelisib is also undergoing phase II DYNAMO study to determine its efficacy in indolent non-Hodgkin lymphoma (iNHL) patients. The company is currently in the process of enrolling patients under the study and is expected to announce the study data in the third quarter of 2016. Apart from the mentioned studies, duvelisib is part of the company’s other significant studies as well.
Duvelisib has been accorded Fast Track designation by the Food and Drug Administration (FDA) for the treatment of FL patients and CLL patients, who have received a specified number of prior therapies.
The stock of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) ended the previous session 3.74% down at $8.49.